Global Idiopathic Pulmonary Fibrosis Market 2023-2027

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	164 Pages	TechNavio	March, 2023	INF17873856

Best Price Guarantee
Price	from $2,500
Length	164 Pages
Publisher	TechNavio
Published Date	March, 2023
SKU	INF17873856

Global Idiopathic Pulmonary Fibrosis Market 2023-2027

Technavio has been monitoring the idiopathic pulmonary fibrosis market and is forecast to grow by $1360.99 mn during 2022-2027, accelerating at a CAGR of 6.68% during the forecast period. Our report on the idiopathic pulmonary fibrosis market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of respiratory diseases, the growing geriatric population, and the increase in the number of smokers.

Technavio's idiopathic pulmonary fibrosis market is segmented as below:

By Route Of Administration

Oral
Parenteral

By Drug Class

Systemic corticosteroids
Immunosuppressants
Tyrosine kinase inhibitors
Anti-fibrotic agents

By Geography

North America
Europe
Asia
Rest of World (ROW)

This study identifies the increase in drug pipeline for IPF as one of the prime reasons driving the idiopathic pulmonary fibrosis market growth during the next few years. Also, the development of novel drugs for treatment of IPF and the emergence of new patterns of IPF will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the idiopathic pulmonary fibrosis market covers the following areas:

Idiopathic pulmonary fibrosis market sizing
Idiopathic pulmonary fibrosis market forecast
Idiopathic pulmonary fibrosis market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading idiopathic pulmonary fibrosis market vendors that include Alembic Pharmaceuticals Ltd., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celix Pharma Ltd., Cipla Ltd., Daewoong Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., FibroGen Inc., Galapagos NV, Galecto Inc., GNI Group Ltd., Horizon Therapeutics Plc, Intas Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Liminal BioSciences Inc., MediciNova Inc., Merck and Co. Inc., Mission Therapeutics, Novartis AG, Shionogi and Co. Ltd., and United Therapeutics Corp. Also, the idiopathic pulmonary fibrosis market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary: 1.1 Market overview; Exhibit 01: Executive Summary - Chart on Market Overview; Exhibit 02: Executive Summary - Data Table on Market Overview; Exhibit 03: Executive Summary - Chart on Global Market Characteristics; Exhibit 04: Executive Summary - Chart on Market by Geography; Exhibit 05: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibit 06: Executive Summary - Chart on Market Segmentation by Drug Class; Exhibit 07: Executive Summary - Chart on Incremental Growth; Exhibit 08: Executive Summary - Data Table on Incremental Growth; Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Exhibit 10: Parent market; Exhibit 11: Market Characteristics
3 Market Sizing: 3.1 Market definition; Exhibit 12: Offerings of vendors included in the market definition; 3.2 Market segment analysis; Exhibit 13: Market segments; 3.3 Market size 2022; 3.4 Market outlook: Forecast for 2022-2027; Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million); Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million); Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%); Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size: 4.1 Global idiopathic pulmonary fibrosis market 2017 - 2021; Exhibit 18: Historic Market Size - Data Table on Global idiopathic pulmonary fibrosis market 2017 - 2021 ($ million); 4.2 Route of Administration Segment Analysis 2017 - 2021; Exhibit 19: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million); 4.3 Drug Class Segment Analysis 2017 - 2021; Exhibit 20: Historic Market Size - Drug Class Segment 2017 - 2021 ($ million); 4.4 Geography Segment Analysis 2017 - 2021; Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million); 4.5 Country Segment Analysis 2017 - 2021; Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis: 5.1 Five forces summary; Exhibit 23: Five forces analysis - Comparison between 2022 and 2027; 5.2 Bargaining power of buyers; Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027; 5.3 Bargaining power of suppliers; Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027; 5.4 Threat of new entrants; Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027; 5.5 Threat of substitutes; Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027; 5.6 Threat of rivalry; Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027; 5.7 Market condition; Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Route of Administration: 6.1 Market segments; Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%); Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%); 6.2 Comparison by Route of Administration; Exhibit 32: Chart on Comparison by Route of Administration; Exhibit 33: Data Table on Comparison by Route of Administration; 6.3 Oral - Market size and forecast 2022-2027; Exhibit 34: Chart on Oral - Market size and forecast 2022-2027 ($ million); Exhibit 35: Data Table on Oral - Market size and forecast 2022-2027 ($ million); Exhibit 36: Chart on Oral - Year-over-year growth 2022-2027 (%); Exhibit 37: Data Table on Oral - Year-over-year growth 2022-2027 (%); 6.4 Parenteral - Market size and forecast 2022-2027; Exhibit 38: Chart on Parenteral - Market size and forecast 2022-2027 ($ million); Exhibit 39: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million); Exhibit 40: Chart on Parenteral - Year-over-year growth 2022-2027 (%); Exhibit 41: Data Table on Parenteral - Year-over-year growth 2022-2027 (%); 6.5 Market opportunity by Route of Administration; Exhibit 42: Market opportunity by Route of Administration ($ million); Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)
7 Market Segmentation by Drug Class: 7.1 Market segments; Exhibit 44: Chart on Drug Class - Market share 2022-2027 (%); Exhibit 45: Data Table on Drug Class - Market share 2022-2027 (%); 7.2 Comparison by Drug Class; Exhibit 46: Chart on Comparison by Drug Class; Exhibit 47: Data Table on Comparison by Drug Class; 7.3 Systemic corticosteroids - Market size and forecast 2022-2027; Exhibit 48: Chart on Systemic corticosteroids - Market size and forecast 2022-2027 ($ million); Exhibit 49: Data Table on Systemic corticosteroids - Market size and forecast 2022-2027 ($ million); Exhibit 50: Chart on Systemic corticosteroids - Year-over-year growth 2022-2027 (%); Exhibit 51: Data Table on Systemic corticosteroids - Year-over-year growth 2022-2027 (%); 7.4 Immunosuppressants - Market size and forecast 2022-2027; Exhibit 52: Chart on Immunosuppressants - Market size and forecast 2022-2027 ($ million); Exhibit 53: Data Table on Immunosuppressants - Market size and forecast 2022-2027 ($ million); Exhibit 54: Chart on Immunosuppressants - Year-over-year growth 2022-2027 (%); Exhibit 55: Data Table on Immunosuppressants - Year-over-year growth 2022-2027 (%); 7.5 Tyrosine kinase inhibitors - Market size and forecast 2022-2027; Exhibit 56: Chart on Tyrosine kinase inhibitors - Market size and forecast 2022-2027 ($ million); Exhibit 57: Data Table on Tyrosine kinase inhibitors - Market size and forecast 2022-2027 ($ million); Exhibit 58: Chart on Tyrosine kinase inhibitors - Year-over-year growth 2022-2027 (%); Exhibit 59: Data Table on Tyrosine kinase inhibitors - Year-over-year growth 2022-2027 (%); 7.6 Anti-fibrotic agents - Market size and forecast 2022-2027; Exhibit 60: Chart on Anti-fibrotic agents - Market size and forecast 2022-2027 ($ million); Exhibit 61: Data Table on Anti-fibrotic agents - Market size and forecast 2022-2027 ($ million); Exhibit 62: Chart on Anti-fibrotic agents - Year-over-year growth 2022-2027 (%); Exhibit 63: Data Table on Anti-fibrotic agents - Year-over-year growth 2022-2027 (%); 7.7 Market opportunity by Drug Class; Exhibit 64: Market opportunity by Drug Class ($ million); Exhibit 65: Data Table on Market opportunity by Drug Class ($ million)
8 Customer Landscape: 8.1 Customer landscape overview; Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape: 9.1 Geographic segmentation; Exhibit 67: Chart on Market share by geography 2022-2027 (%); Exhibit 68: Data Table on Market share by geography 2022-2027 (%); 9.2 Geographic comparison; Exhibit 69: Chart on Geographic comparison; Exhibit 70: Data Table on Geographic comparison; 9.3 North America - Market size and forecast 2022-2027; Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million); Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million); Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%); Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%); 9.4 Europe - Market size and forecast 2022-2027; Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million); Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million); Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%); Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%); 9.5 Asia - Market size and forecast 2022-2027; Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million); Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million); Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%); Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%); 9.6 Rest of World (ROW) - Market size and forecast 2022-2027; Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million); Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million); Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%); Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%); 9.7 US - Market size and forecast 2022-2027; Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million); Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million); Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%); Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%); 9.8 China - Market size and forecast 2022-2027; Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ million); Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ million); Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%); Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%); 9.9 Japan - Market size and forecast 2022-2027; Exhibit 95: Chart on Japan - Market size and forecast 2022-2027 ($ million); Exhibit 96: Data Table on Japan - Market size and forecast 2022-2027 ($ million); Exhibit 97: Chart on Japan - Year-over-year growth 2022-2027 (%); Exhibit 98: Data Table on Japan - Year-over-year growth 2022-2027 (%); 9.10 Germany - Market size and forecast 2022-2027; Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ million); Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ million); Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%); Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%); 9.11 UK - Market size and forecast 2022-2027; Exhibit 103: Chart on UK - Market size and forecast 2022-2027 ($ million); Exhibit 104: Data Table on UK - Market size and forecast 2022-2027 ($ million); Exhibit 105: Chart on UK - Year-over-year growth 2022-2027 (%); Exhibit 106: Data Table on UK - Year-over-year growth 2022-2027 (%); 9.12 Market opportunity by geography; Exhibit 107: Market opportunity by geography ($ million); Exhibit 108: Data Tables on Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends: 10.1 Market drivers; 10.2 Market challenges; 10.3 Impact of drivers and challenges; Exhibit 109: Impact of drivers and challenges in 2022 and 2027; 10.4 Market trends
11 Vendor Landscape: 11.1 Overview; 11.2 Vendor landscape; Exhibit 110: Overview on Criticality of inputs and Factors of differentiation; 11.3 Landscape disruption; Exhibit 111: Overview on factors of disruption; 11.4 Industry risks; Exhibit 112: Impact of key risks on business
12 Vendor Analysis: 12.1 Vendors covered; Exhibit 113: Vendors covered; 12.2 Market positioning of vendors; Exhibit 114: Matrix on vendor position and classification; 12.3 AstraZeneca Plc; Exhibit 115: AstraZeneca Plc - Overview; Exhibit 116: AstraZeneca Plc - Product / Service; Exhibit 117: AstraZeneca Plc - Key news; Exhibit 118: AstraZeneca Plc - Key offerings; 12.4 Boehringer Ingelheim International GmbH; Exhibit 119: Boehringer Ingelheim International GmbH - Overview; Exhibit 120: Boehringer Ingelheim International GmbH - Business segments; Exhibit 121: Boehringer Ingelheim International GmbH - Key news; Exhibit 122: Boehringer Ingelheim International GmbH - Key offerings; Exhibit 123: Boehringer Ingelheim International GmbH - Segment focus; 12.5 Bristol Myers Squibb Co.; Exhibit 124: Bristol Myers Squibb Co. - Overview; Exhibit 125: Bristol Myers Squibb Co. - Product / Service; Exhibit 126: Bristol Myers Squibb Co. - Key news; Exhibit 127: Bristol Myers Squibb Co. - Key offerings; 12.6 Cipla Ltd.; Exhibit 128: Cipla Ltd. - Overview; Exhibit 129: Cipla Ltd. - Business segments; Exhibit 130: Cipla Ltd. - Key news; Exhibit 131: Cipla Ltd. - Key offerings; Exhibit 132: Cipla Ltd. - Segment focus; 12.7 F. Hoffmann La Roche Ltd.; Exhibit 133: F. Hoffmann La Roche Ltd. - Overview; Exhibit 134: F. Hoffmann La Roche Ltd. - Business segments; Exhibit 135: F. Hoffmann La Roche Ltd. - Key news; Exhibit 136: F. Hoffmann La Roche Ltd. - Key offerings; Exhibit 137: F. Hoffmann La Roche Ltd. - Segment focus; 12.8 FibroGen Inc.; Exhibit 138: FibroGen Inc. - Overview; Exhibit 139: FibroGen Inc. - Product / Service; Exhibit 140: FibroGen Inc. - Key offerings; 12.9 Galapagos NV; Exhibit 141: Galapagos NV - Overview; Exhibit 142: Galapagos NV - Product / Service; Exhibit 143: Galapagos NV - Key offerings; 12.10 GNI Group Ltd.; Exhibit 144: GNI Group Ltd. - Overview; Exhibit 145: GNI Group Ltd. - Product / Service; Exhibit 146: GNI Group Ltd. - Key offerings; 12.11 Horizon Therapeutics Plc; Exhibit 147: Horizon Therapeutics Plc - Overview; Exhibit 148: Horizon Therapeutics Plc - Business segments; Exhibit 149: Horizon Therapeutics Plc - Key news; Exhibit 150: Horizon Therapeutics Plc - Key offerings; Exhibit 151: Horizon Therapeutics Plc - Segment focus; 12.12 Jubilant Pharmova Ltd.; Exhibit 152: Jubilant Pharmova Ltd. - Overview; Exhibit 153: Jubilant Pharmova Ltd. - Business segments; Exhibit 154: Jubilant Pharmova Ltd. - Key news; Exhibit 155: Jubilant Pharmova Ltd. - Key offerings; Exhibit 156: Jubilant Pharmova Ltd. - Segment focus; 12.13 Liminal BioSciences Inc.; Exhibit 157: Liminal BioSciences Inc. - Overview; Exhibit 158: Liminal BioSciences Inc. - Product / Service; Exhibit 159: Liminal BioSciences Inc. - Key offerings; 12.14 MediciNova Inc.; Exhibit 160: MediciNova Inc. - Overview; Exhibit 161: MediciNova Inc. - Product / Service; Exhibit 162: MediciNova Inc. - Key offerings; 12.15 Novartis AG; Exhibit 163: Novartis AG - Overview; Exhibit 164: Novartis AG - Business segments; Exhibit 165: Novartis AG - Key offerings; Exhibit 166: Novartis AG - Segment focus; 12.16 Shionogi and Co. Ltd.; Exhibit 167: Shionogi and Co. Ltd. - Overview; Exhibit 168: Shionogi and Co. Ltd. - Product / Service; Exhibit 169: Shionogi and Co. Ltd. - Key offerings; 12.17 United Therapeutics Corp.; Exhibit 170: United Therapeutics Corp. - Overview; Exhibit 171: United Therapeutics Corp. - Product / Service; Exhibit 172: United Therapeutics Corp. - Key offerings
13 Appendix: 13.1 Scope of the report; 13.2 Inclusions and exclusions checklist; Exhibit 173: Inclusions checklist; Exhibit 174: Exclusions checklist; 13.3 Currency conversion rates for US$; Exhibit 175: Currency conversion rates for US$; 13.4 Research methodology; Exhibit 176: Research methodology; Exhibit 177: Validation techniques employed for market sizing; Exhibit 178: Information sources; 13.5 List of abbreviations; Exhibit 179: List of abbreviations; Exhibits:; Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market by Geography; Exhibits5: Executive Summary - Chart on Market Segmentation by Route of Administration; Exhibits6: Executive Summary - Chart on Market Segmentation by Drug Class; Exhibits7: Executive Summary - Chart on Incremental Growth; Exhibits8: Executive Summary - Data Table on Incremental Growth; Exhibits9: Executive Summary - Chart on Vendor Market Positioning; Exhibits10: Parent market; Exhibits11: Market Characteristics; Exhibits12: Offerings of vendors included in the market definition; Exhibits13: Market segments; Exhibits14: Chart on Global - Market size and forecast 2022-2027 ($ million); Exhibits15: Data Table on Global - Market size and forecast 2022-2027 ($ million); Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%); Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%); Exhibits18: Historic Market Size - Data Table on Global idiopathic pulmonary fibrosis market 2017 - 2021 ($ million); Exhibits19: Historic Market Size - Route of Administration Segment 2017 - 2021 ($ million); Exhibits20: Historic Market Size - Drug Class Segment 2017 - 2021 ($ million); Exhibits21: Historic Market Size - Geography Segment 2017 - 2021 ($ million); Exhibits22: Historic Market Size - Country Segment 2017 - 2021 ($ million); Exhibits23: Five forces analysis - Comparison between 2022 and 2027; Exhibits24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027; Exhibits25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027; Exhibits26: Threat of new entrants - Impact of key factors in 2022 and 2027; Exhibits27: Threat of substitutes - Impact of key factors in 2022 and 2027; Exhibits28: Threat of rivalry - Impact of key factors in 2022 and 2027; Exhibits29: Chart on Market condition - Five forces 2022 and 2027; Exhibits30: Chart on Route of Administration - Market share 2022-2027 (%); Exhibits31: Data Table on Route of Administration - Market share 2022-2027 (%); Exhibits32: Chart on Comparison by Route of Administration; Exhibits33: Data Table on Comparison by Route of Administration; Exhibits34: Chart on Oral - Market size and forecast 2022-2027 ($ million); Exhibits35: Data Table on Oral - Market size and forecast 2022-2027 ($ million); Exhibits36: Chart on Oral - Year-over-year growth 2022-2027 (%); Exhibits37: Data Table on Oral - Year-over-year growth 2022-2027 (%); Exhibits38: Chart on Parenteral - Market size and forecast 2022-2027 ($ million); Exhibits39: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million); Exhibits40: Chart on Parenteral - Year-over-year growth 2022-2027 (%); Exhibits41: Data Table on Parenteral - Year-over-year growth 2022-2027 (%); Exhibits42: Market opportunity by Route of Administration ($ million); Exhibits43: Data Table on Market opportunity by Route of Administration ($ million); Exhibits44: Chart on Drug Class - Market share 2022-2027 (%); Exhibits45: Data Table on Drug Class - Market share 2022-2027 (%); Exhibits46: Chart on Comparison by Drug Class; Exhibits47: Data Table on Comparison by Drug Class; Exhibits48: Chart on Systemic corticosteroids - Market size and forecast 2022-2027 ($ million); Exhibits49: Data Table on Systemic corticosteroids - Market size and forecast 2022-2027 ($ million); Exhibits50: Chart on Systemic corticosteroids - Year-over-year growth 2022-2027 (%); Exhibits51: Data Table on Systemic corticosteroids - Year-over-year growth 2022-2027 (%); Exhibits52: Chart on Immunosuppressants - Market size and forecast 2022-2027 ($ million); Exhibits53: Data Table on Immunosuppressants - Market size and forecast 2022-2027 ($ million); Exhibits54: Chart on Immunosuppressants - Year-over-year growth 2022-2027 (%); Exhibits55: Data Table on Immunosuppressants - Year-over-year growth 2022-2027 (%); Exhibits56: Chart on Tyrosine kinase inhibitors - Market size and forecast 2022-2027 ($ million); Exhibits57: Data Table on Tyrosine kinase inhibitors - Market size and forecast 2022-2027 ($ million); Exhibits58: Chart on Tyrosine kinase inhibitors - Year-over-year growth 2022-2027 (%); Exhibits59: Data Table on Tyrosine kinase inhibitors - Year-over-year growth 2022-2027 (%); Exhibits60: Chart on Anti-fibrotic agents - Market size and forecast 2022-2027 ($ million); Exhibits61: Data Table on Anti-fibrotic agents - Market size and forecast 2022-2027 ($ million); Exhibits62: Chart on Anti-fibrotic agents - Year-over-year growth 2022-2027 (%); Exhibits63: Data Table on Anti-fibrotic agents - Year-over-year growth 2022-2027 (%); Exhibits64: Market opportunity by Drug Class ($ million); Exhibits65: Data Table on Market opportunity by Drug Class ($ million); Exhibits66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits67: Chart on Market share by geography 2022-2027 (%); Exhibits68: Data Table on Market share by geography 2022-2027 (%); Exhibits69: Chart on Geographic comparison; Exhibits70: Data Table on Geographic comparison; Exhibits71: Chart on North America - Market size and forecast 2022-2027 ($ million); Exhibits72: Data Table on North America - Market size and forecast 2022-2027 ($ million); Exhibits73: Chart on North America - Year-over-year growth 2022-2027 (%); Exhibits74: Data Table on North America - Year-over-year growth 2022-2027 (%); Exhibits75: Chart on Europe - Market size and forecast 2022-2027 ($ million); Exhibits76: Data Table on Europe - Market size and forecast 2022-2027 ($ million); Exhibits77: Chart on Europe - Year-over-year growth 2022-2027 (%); Exhibits78: Data Table on Europe - Year-over-year growth 2022-2027 (%); Exhibits79: Chart on Asia - Market size and forecast 2022-2027 ($ million); Exhibits80: Data Table on Asia - Market size and forecast 2022-2027 ($ million); Exhibits81: Chart on Asia - Year-over-year growth 2022-2027 (%); Exhibits82: Data Table on Asia - Year-over-year growth 2022-2027 (%); Exhibits83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million); Exhibits84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million); Exhibits85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%); Exhibits86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%); Exhibits87: Chart on US - Market size and forecast 2022-2027 ($ million); Exhibits88: Data Table on US - Market size and forecast 2022-2027 ($ million); Exhibits89: Chart on US - Year-over-year growth 2022-2027 (%); Exhibits90: Data Table on US - Year-over-year growth 2022-2027 (%); Exhibits91: Chart on China - Market size and forecast 2022-2027 ($ million); Exhibits92: Data Table on China - Market size and forecast 2022-2027 ($ million); Exhibits93: Chart on China - Year-over-year growth 2022-2027 (%); Exhibits94: Data Table on China - Year-over-year growth 2022-2027 (%); Exhibits95: Chart on Japan - Market size and forecast 2022-2027 ($ million); Exhibits96: Data Table on Japan - Market size and forecast 2022-2027 ($ million); Exhibits97: Chart on Japan - Year-over-year growth 2022-2027 (%); Exhibits98: Data Table on Japan - Year-over-year growth 2022-2027 (%); Exhibits99: Chart on Germany - Market size and forecast 2022-2027 ($ million); Exhibits100: Data Table on Germany - Market size and forecast 2022-2027 ($ million); Exhibits101: Chart on Germany - Year-over-year growth 2022-2027 (%); Exhibits102: Data Table on Germany - Year-over-year growth 2022-2027 (%); Exhibits103: Chart on UK - Market size and forecast 2022-2027 ($ million); Exhibits104: Data Table on UK - Market size and forecast 2022-2027 ($ million); Exhibits105: Chart on UK - Year-over-year growth 2022-2027 (%); Exhibits106: Data Table on UK - Year-over-year growth 2022-2027 (%); Exhibits107: Market opportunity by geography ($ million); Exhibits108: Data Tables on Market opportunity by geography ($ million); Exhibits109: Impact of drivers and challenges in 2022 and 2027; Exhibits110: Overview on Criticality of inputs and Factors of differentiation; Exhibits111: Overview on factors of disruption; Exhibits112: Impact of key risks on business; Exhibits113: Vendors covered; Exhibits114: Matrix on vendor position and classification; Exhibits115: AstraZeneca Plc - Overview; Exhibits116: AstraZeneca Plc - Product / Service; Exhibits117: AstraZeneca Plc - Key news; Exhibits118: AstraZeneca Plc - Key offerings; Exhibits119: Boehringer Ingelheim International GmbH - Overview; Exhibits120: Boehringer Ingelheim International GmbH - Business segments; Exhibits121: Boehringer Ingelheim International GmbH - Key news; Exhibits122: Boehringer Ingelheim International GmbH - Key offerings; Exhibits123: Boehringer Ingelheim International GmbH - Segment focus; Exhibits124: Bristol Myers Squibb Co. - Overview; Exhibits125: Bristol Myers Squibb Co. - Product / Service; Exhibits126: Bristol Myers Squibb Co. - Key news; Exhibits127: Bristol Myers Squibb Co. - Key offerings; Exhibits128: Cipla Ltd. - Overview; Exhibits129: Cipla Ltd. - Business segments; Exhibits130: Cipla Ltd. - Key news; Exhibits131: Cipla Ltd. - Key offerings; Exhibits132: Cipla Ltd. - Segment focus; Exhibits133: F. Hoffmann La Roche Ltd. - Overview; Exhibits134: F. Hoffmann La Roche Ltd. - Business segments; Exhibits135: F. Hoffmann La Roche Ltd. - Key news; Exhibits136: F. Hoffmann La Roche Ltd. - Key offerings; Exhibits137: F. Hoffmann La Roche Ltd. - Segment focus; Exhibits138: FibroGen Inc. - Overview; Exhibits139: FibroGen Inc. - Product / Service; Exhibits140: FibroGen Inc. - Key offerings; Exhibits141: Galapagos NV - Overview; Exhibits142: Galapagos NV - Product / Service; Exhibits143: Galapagos NV - Key offerings; Exhibits144: GNI Group Ltd. - Overview; Exhibits145: GNI Group Ltd. - Product / Service; Exhibits146: GNI Group Ltd. - Key offerings; Exhibits147: Horizon Therapeutics Plc - Overview; Exhibits148: Horizon Therapeutics Plc - Business segments; Exhibits149: Horizon Therapeutics Plc - Key news; Exhibits150: Horizon Therapeutics Plc - Key offerings; Exhibits151: Horizon Therapeutics Plc - Segment focus; Exhibits152: Jubilant Pharmova Ltd. - Overview; Exhibits153: Jubilant Pharmova Ltd. - Business segments; Exhibits154: Jubilant Pharmova Ltd. - Key news; Exhibits155: Jubilant Pharmova Ltd. - Key offerings; Exhibits156: Jubilant Pharmova Ltd. - Segment focus; Exhibits157: Liminal BioSciences Inc. - Overview; Exhibits158: Liminal BioSciences Inc. - Product / Service; Exhibits159: Liminal BioSciences Inc. - Key offerings; Exhibits160: MediciNova Inc. - Overview; Exhibits161: MediciNova Inc. - Product / Service; Exhibits162: MediciNova Inc. - Key offerings; Exhibits163: Novartis AG - Overview; Exhibits164: Novartis AG - Business segments; Exhibits165: Novartis AG - Key offerings; Exhibits166: Novartis AG - Segment focus; Exhibits167: Shionogi and Co. Ltd. - Overview; Exhibits168: Shionogi and Co. Ltd. - Product / Service; Exhibits169: Shionogi and Co. Ltd. - Key offerings; Exhibits170: United Therapeutics Corp. - Overview; Exhibits171: United Therapeutics Corp. - Product / Service; Exhibits172: United Therapeutics Corp. - Key offerings; Exhibits173: Inclusions checklist; Exhibits174: Exclusions checklist; Exhibits175: Currency conversion rates for US$; Exhibits176: Research methodology; Exhibits177: Validation techniques employed for market sizing; Exhibits178: Information sources; Exhibits179: List of abbreviations